Harmony Biosciences Holdings (HRMY)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 84.01% | 86.06% | 84.62% | 84.66% | 84.56% | 85.17% | 93.20% | 93.23% | 92.95% | 94.12% | 83.35% |
| Operating profit margin | 35.01% | 39.28% | 30.81% | 29.48% | 28.68% | 26.41% | 34.49% | 34.56% | 32.55% | 28.15% | 23.99% |
| Pretax margin | 31.61% | 35.02% | 28.11% | 26.38% | 24.98% | 22.20% | 20.80% | 18.36% | 13.92% | 5.38% | 10.79% |
| Net profit margin | 23.49% | 29.69% | 42.02% | 41.98% | 43.30% | 40.63% | 18.16% | 16.74% | 12.87% | 4.93% | 9.94% |
Harmony Biosciences Holdings Inc has displayed a consistent and healthy trend in its profitability ratios over the past eight quarters. The gross profit margin has remained relatively stable, ranging from 79.17% to 81.02% during this period, indicating the company's ability to efficiently generate revenue after accounting for the cost of goods sold.
The operating profit margin has shown some fluctuations but generally demonstrates a positive trend, with values ranging from 25.25% to 36.80%. This indicates that Harmony Biosciences has been effectively managing its operating expenses and is generating strong profits from its core business operations.
Similarly, the pretax margin and net profit margin have exhibited positive trends, with values ranging from 16.14% to 32.81% and 14.71% to 41.44%, respectively. These margins reflect the company's ability to control its costs and generate profits before and after accounting for taxes.
Overall, Harmony Biosciences Holdings Inc has shown consistent profitability and efficient cost management over the analyzed period, indicating a strong financial performance and sustainable business operations.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 23.67% | 25.64% | 19.32% | 18.61% | 17.84% | 15.73% | 21.85% | 21.67% | 20.19% | 17.04% | 15.56% |
| Return on assets (ROA) | 15.88% | 19.38% | 26.34% | 26.50% | 26.93% | 24.19% | 11.51% | 10.49% | 7.98% | 2.99% | 6.45% |
| Return on total capital | 29.75% | 30.06% | 22.06% | 21.18% | 20.29% | 18.97% | 25.29% | 24.86% | 23.25% | 19.49% | 17.38% |
| Return on equity (ROE) | 27.59% | 31.32% | 41.27% | 42.77% | 45.05% | 45.27% | 23.57% | 22.70% | 18.55% | 7.68% | 18.34% |
Harmony Biosciences Holdings Inc's profitability ratios reflect its ability to generate returns for its stakeholders. Starting with Operating ROA, the company's operational efficiency improved in Q4 2023 compared to the previous quarters, with a rise from 17.84% in Q4 2022 to 23.67%. This indicates that the company effectively utilizes its assets to generate operating income. ROA also improved, reaching a peak of 26.50% in Q1 2023, showcasing the company's overall profitability relative to its total assets.
Return on total capital remained relatively steady, with Q3 and Q4 2023 showing a slight decline compared to the previous quarters, yet remaining above 20%. This ratio measures the company's ability to generate profits from the total capital employed, including debt and equity. Notably, ROE demonstrated consistent growth, reaching its highest point of 42.77% in Q1 2023, reflecting the company's efficiency in generating profits relative to shareholder equity.
Overall, Harmony Biosciences Holdings Inc has shown strong profitability performance, as evidenced by the positive trends in its profitability ratios. The company's ability to effectively manage its assets, generate profits from its capital, and deliver returns to its shareholders underscores its financial strength and operational excellence.